Citius Pharma Q2 2026: $5.6M H1 LYMPHIR revenue, 80% gross margins; raises $36.5M at Citius Oncology

Citius Pharmaceuticals, Inc.

2026-Q2 EPS reported -$1.34 revenue$5,611,409

Net product revenue $1.7M in Q2 (launch quarter); $5.6M in H1 2026 vs. zero a year ago.
Payer coverage near 100% of commercial lives; 83% of target accounts on formulary or in review.
Citius Oncology secured up to $36.5M debt/equity; Citius Pharma raised $5M direct offering.
Net loss $21.2M in Q2 ($0.95/share) vs. $10.9M a year ago; includes $19.7M CMO cancellation charge.
First LYMPHIR shipment to Europe via Uniphar; positive Phase 1 combo data with pembrolizumab and pre-CAR-T.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.